SEARCH:   Advanced

Blood, 26 February 2009, Vol. 113, No. 9, pp. 2096-2103. Prepublished online as a Blood First Edition Paper on January 6, 2009; DOI 10.1182/blood-2008-03-145862. This Article Full Text Full Text (PDF) Supplemental Tables and Figures All Versions of this Article: blood-2008-03-145862v1 113/9/2096    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kuwatsuka, Y. Articles by Kodera, Y. Search for Related Content PubMed PubMed Citation Articles by Kuwatsuka, Y. Articles by Kodera, Y. Related Collections Transplantation Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes Yachiyo Kuwatsuka1, Koichi Miyamura1, Ritsuro Suzuki2, Masaharu Kasai3, Atsuo Maruta4, Hiroyasu Ogawa5, Ryuji Tanosaki6, Satoshi Takahashi7, Kyuhei Koda8, Kazuhiro Yago9, Yoshiko Atsuta2, Takashi Yoshida10, Hisashi Sakamaki11, and Yoshihisa Kodera1 1 Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya; 2 Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya; 3 Department of Hematology, Sapporo Hokuyu Hospital, Sapporo; 4 Department of Hematology, Kanagawa Cancer Center, Yokohama; 5 Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka; 6 Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo; 7 Department of Hematology, Institute of Medical Science, The University of Tokyo, Tokyo; 8 Department of Hematology, Asahikawa Red Cross Hospital, Asahikawa; 9 Department of Hematology, Shizuoka General Hospital, Shizuoka; 10 Hematology Department, Toyama Prefectural Hospital, Toyama; and 11 Department of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database. At 3 years, overall survival (OS) of patients with t(8;21) and inv(16) was 50% and 72%, respectively (P = .002). Although no difference was observed when restricted to allogeneic SCT in first complete remission (CR; 84% and 74%), OS of patients with t(8;21) and inv(16) undergoing allogeneic SCT in second or third CR (45% and 86% at 3 years; P = .008) was different. OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84% vs 77%; P = .49) and inv(16) AML (74% vs 59%; P = .86). Patients with inv(16) not in CR did better after allogeneic SCT than those with t(8;21) (70% and 18%; P = .03). Patients with t(8;21) and inv(16) should be managed differently as to the application of SCT. SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020